CLASS II Drug recall · Reported 19 Oct 2016 · FDA Enforcement Report

Marcaine 0.25% (bupivacaine HCl) injection, USP, 125 mg recalled

Hospira Inc. A Pfizer is recalling Marcaine 0.25% (bupivacaine HCl) injection, USP, 125 mg/ (2.5 mg/mL) Multiple-Dose Vial, distributed nationwide in the US. The recall was initiated on 16 Sep 2016 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot #: 60295DD, Ep 1DEC2017
NDC0409-0525, 0409-1559, 0409-1560, 0409-1582, 0409-1587, 0409-1610
Quantity recalled15 vials

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0096-2017
FDA event ID
75156
Recalling firm
Hospira Inc. A Pfizer, Lake Forest, IL
Manufacturer
Hospira, Inc.
Classification
Class II
Status
Terminated
Recall initiated
16 Sep 2016
FDA classified
13 Oct 2016
Reported
19 Oct 2016
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Foreign Material

Timeline

16 Sep 2016Recall initiated by company
13 Oct 2016Classified by FDA+27 days
19 Oct 2016Published in enforcement report+6 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Lack of Assurance of Sterility and Subpotent Drug: defect in glass vial prevented stopper from forming a seal allowing water to ingress and dilute the product causing it to be less than the labeled potency.

Foreign material recalls cover pieces of metal, plastic, glass, wood or other objects that got into the product during processing and could cause injury if eaten.

Product as listed by the FDA

Marcaine 0.25% (bupivacaine HCl) injection, USP, 125 mg/50 mL (2.5 mg/mL), 50 mL Multiple-Dose Vial, Rx only, Hospira, Inc., Lake Forest, IL 60045, NDC 0409-1587-50.

Where it was distributed

Nationwide and Puerto Rico

Nationwide Puerto Rico

Questions about this recall

Why was it recalled?

Lack of Assurance of Sterility and Subpotent Drug: defect in glass vial prevented stopper from forming a seal allowing water to ingress and dilute the product causing it to be less than the labeled potency.

Which lots are affected?

Lot #: 60295DD, Ep 1DEC2017

Where was it sold?

Nationwide and Puerto Rico

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other products in this recall event

1 other product · FDA event 75156
ReportedClassRecallCompanyReasonWhere
CLASS IIMarcaine 0.5% (bupivacaine HCl) injection, USP, 250 mg recalledMarcaineHospira Inc. A PfizerForeign MaterialNationwide

More recalls from Hospira Inc. A Pfizer

All 9

Other Bupivacaine recalls

All 54